Skip to main content
Balaji Amines Ltd. logo

Balaji Amines Ltd. — Investor Relations & Filings

Ticker · BALAMINES ISIN · INE050E01027 LEI · 3358009DS8RG4Z8QBD69 BSE.NS Manufacturing
Filings indexed 743 across all filing types
Latest filing 2025-02-12 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS BALAMINES

About Balaji Amines Ltd.

https://www.balajiamines.com/

Balaji Amines Ltd. is a leading manufacturer specializing in Aliphatic Amines, their derivatives, and specialty chemicals. The company produces a diverse range of products, including Methylamines, Ethylamines, and specialty chemicals such as N-Methyl-2-Pyrrolidone (NMP), Morpholine, Dimethylformamide (DMF), and Gamma-Butyrolactone (GBL). Its portfolio serves critical sectors including pharmaceuticals, agrochemicals, refineries, water treatment, and personal care. Utilizing advanced manufacturing technologies and vertically integrated processes, the company maintains a significant market presence in the production of amines and downstream derivatives. Balaji Amines is recognized for its large-scale production capacity and its role as a key supplier of essential chemical intermediates used in the synthesis of active pharmaceutical ingredients and crop protection chemicals.

Recent filings

Filing Released Lang Actions
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release announcing unaudited financial results for the quarter and nine months ended December 31, 2024. It contains detailed financial highlights including revenue, EBITDA, PAT, margins, and volumes for Q3FY25 and 9MFY25, along with commentary from the Managing Director and updates on new projects and expansions. The document is about 11,349 characters long, which is substantial and contains actual financial data and analysis, not just a brief announcement or a link to a report. It is not a full annual report but a quarterly financial update with substantive financial information. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-02-12 English
Financial Result Updates
Regulatory Filings
2025-02-12 English
Outcome of Board Meeting
Regulatory Filings
2025-02-12 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-02-05 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying them of an upcoming Board Meeting scheduled to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024. It also mentions the closure of the trading window in compliance with insider trading regulations. The document is short (1763 characters) and serves as an intimation or announcement rather than containing the actual financial results or detailed report. Therefore, it is an announcement related to a Board Meeting and financial results, not the financial report itself. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-02-05 English
Action(s) taken or orders passed
Regulatory Filings
2025-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.